Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Celsius Resources Limited		
ABN 95 009	9 162 949	
We (tl	he entity) give ASX the following	information.
	1 - All issues ust complete the relevant sections (attach si	heets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	493,900
	Principal terms of the <sup>+</sup> securities (e.g. if options, exercise price and expiry date; if partly paid <sup>+</sup> securities, the amount outstanding and due dates for payment; if <sup>+</sup> convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$0.01 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of listed options
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the <sup>+</sup> securities the	Yes
	subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	24 November 2017
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6f Number of \*securities issued under an exception in rule 7.2

493,900

6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.

N/A

6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Under 7.1 – 97,717,948

Under 7.1A - 17,828,578

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

28 June 2018

8	Number and <sup>+</sup> class of all <sup>+</sup> securities
	quoted on ASX (including the
	+securities in section 2 if applicable)

Number	+Class
691,561,375	Ordinary Fully Paid Shares
21,875,000	Fully Paid Ordinary Shares (in escrow to 13 September 2018)
43,879,507	Options exercise price \$0.01, expiring 30 December 2018

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
3,000,000	Unlisted options exercisable at \$0.05 expiring 18 May 2020
2,000,000	Unlisted options exercisable at \$0.075 expiring 19 May 2020

<sup>+</sup> See chapter 19 for defined terms.

2,000,000	Unlisted options exercisable at \$0.10 expiring 19 May 2020
2,000,000	Unlisted options exercisable at \$0.125 expiring 19 May 2020
16,000,000	Unlisted options exercisable at \$0.05 expiring 18 August 2020
1,000,000	Unlisted options exercisable at \$0.175 expiring 5 January 2021
1,500,000	Unlisted options exercisable at \$0.225 expiring 5 January 2021
6,000,000	Unlisted options exercisable at \$0.075 expiring 12 January 2021
2,000,000	Unlisted options exercisable at \$0.175 expiring 8 December 2020
2,000,000	Unlisted options exercisable at \$0.205 expiring 8 December 2020
2,000,000	Unlisted options exercisable at \$0.225 expiring 8 December 2020
2,000,000	Unlisted options exercisable at \$0.175 expiring 6 February 2020
1,000,000	Unlisted options exercisable at \$0.13 expiring 16 April 2020
1,000,000	Unlisted options exercisable at \$0.16 expiring 16 April 2020
6,000,000	Unlisted options exercisable at \$0.175 expiring 16 April 2021

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No dividend policy established as the Company is still in exploration phase

## Part 2 - Pro rata issue

Is security holder approval required?	Not applicable
Is the issue renounceable or non-renounceable?	
Ratio in which the *securities will be offered	
*Class of *securities to which the offer relates	
<sup>+</sup> Record date to determine entitlements	
Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
Policy for deciding entitlements in relation to fractions	
Names of countries in which the entity has security holders who will not be sent new offer documents	
Note: Security holders must be told how their entitlements are to be dealt with.	
Cross reference: rule 7.7.	
Closing date for receipt of acceptances or renunciations	
Names of any underwriters	
Amount of any underwriting fee or commission	
Names of any brokers to the issue	
Fee or commission payable to the broker to the issue	
	renounceable?  Ratio in which the *securities will be offered  *Class of *securities to which the offer relates  *Record date to determine entitlements  Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  Policy for deciding entitlements in relation to fractions  Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.  Closing date for receipt of acceptances or renunciations  Names of any underwriters  Amount of any underwriting fee or commission  Names of any brokers to the issue  Fee or commission payable to the

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B New issue announcement

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	
Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities		
34	Type of *securities (tick one)	
(a)	*Securities described in Part 1	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

(b)	All other +securities		
		f the escrowed period, partly paid securities that become fully paid, employee ds, securities issued on expiry or conversion of convertible securities	
Entiti	ies that have ticked box 34(a)		
Addit	tional securities forming a new cla	ss of securities	
Tick to docume	o indicate you are providing the informati ents	on or	
35	1 1	securities, the names of the 20 largest holders of the number and percentage of additional *securities held by	
36	If the *securities are *equity *securities setting out the numb 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	securities, a distribution schedule of the additional per of holders in the categories	
37	A copy of any trust deed for the	e additional <sup>+</sup> securities	
Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		

<sup>+</sup> See chapter 19 for defined terms.

41 Reason for request for quotation

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another \*security, clearly identify that other \*security)

Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in clause 38)

Number	+Class

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 28/06/2018

(Company secretary)

Print name: Melanie Ross

+ See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exc	ceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	459,316,544	
Add the following:	300,000 (options exercised 25/8/17)	
Number of fully paid <sup>+</sup> ordinary securities	430,000 (options exercised 29//8/17)	
issued in that 12 month period under an exception in rule 7.2	500,000 (options exercised 13/9/17)	
Number of fully paid <sup>+</sup> ordinary securities     instead in that 40 growth paried with	43,750,000 (shares issued 13/9/17)	
issued in that 12 month period with shareholder approval	1,000,000 (options exercised 20/10/17)	
Number of partly paid +ordinary	1,500,000 (options exercised 1/11/17)	
securities that became fully paid in that 12 month period	1,496,913 (options exercised 6/11/17)	
Note:	325,592 (options exercised 17/11/17)	
Include only ordinary securities here –     other classes of equity securities cannot     be added	1,216,667 (options exercised 28/11/17)	
<ul> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>	2,000,000 (unlisted options approved 27/7/17, issued 5/12/17)	
It may be useful to set out issues of securities on different dates as separate	1,490,764 (options exercised 8/12/17)	
line items	1,964,000 (options exercised 15/12/17)	
	1,400,000 (options exercised 21/12/17)	
	820,000 (options exercised 5/1/18)	
	2,624,250 (options exercised 12/1/18)	
	48,600 (options exercised 29/1/18)	
	210,277 (options exercised 6/2/18)	
	56,000 (options exercised 21/2/18)	
	71,636,636 (Shares issued 3/11/17,	

<sup>+</sup> See chapter 19 for defined terms.

	approved 20/3/18)
	300,000 (options exercised 21/3/18)
	5,861,353 (options exercised 29/3/18)
	688,008 (options exercised 16/4/18)
	3,000,000 (unlisted options exercised 16/4/18)
	8,834,208 (options exercised 17/4/18)
	710,357 (options exercised 20/4/18)
	3,106,425 (options exercised 27/4/18)
	10,282,222 (options exercised 2/5/2018)
	414,925 (options exercised 4/5/2018)
	2,000,000 (unlisted options exercised 4/5/2018)
	2,000,000 (unlisted options exercised 15/5/2018)
	1,156,500 (options exercised 15/5/2018)
	8,000,000 (unlisted options exercised 22/5/2018)
	393,598 (options exercised 22/5/2018)
	8,000,000 (unlisted options exercised 31/5/2018)
	152,098 (options exercised 31/5/2018)
	16,216,284 (SPP 1/6/2018)
	690,200 (options exercised 14/6/18)
	400,000 (options exercised 18/6/18)
	493,900 (options exercised 28/6/18)
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil
"A"	664,786,321

# Step 2: Calculate 15% of "A"

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	99,717,948	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	2,000,000 unlisted options issued 16/4/18	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	2,000,000	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	99,717,948	
Note: number must be same as shown in Step 2		
Subtract "C"	2,000,000	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	97,717,948	
Dort 2	[Note: this is the remaining placement capacity under rule 7.1]	

# Part 2

# Rule 7.1A – Additional placement capacity for eligible entities

## Step 1: Calculate "A", the base figure from which the placement

<sup>+</sup> See chapter 19 for defined terms.

capacity is calculated		
"A"	664,786,321	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	66,478,632	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	48,650,054 Placement 11/5/2018	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	48,650,054	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	66,478,632	
Note: number must be same as shown in Step 2		
Subtract "E"	48,650,054	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	17,828,578	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 12 04/03/2013